Neurology Edition: Top Headlines for Week of November 14, 2022

In this edition, neurologic effects of COVID-19 among pediatric populations, FDA accepts NDA for extended-release carbidopa/levodopa, antihistamines could be promising therapy for Parkinson’s disease and more.

Read the full coverage here:

Neurologic effects of COVID-19 persisted among pediatric populations in 2021

FDA accepts NDA for extended-release carbidopa/levodopa Parkinson’s treatment

Antihistamines could be promising adjuvant therapy for Parkinson’s disease

Recurrent head injury linked to affective dysregulation, impulse control

AI-powered detection tool found 85% of aneurysms were not referred for follow-up

References:

LaRovere KL, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3881.

Press Release

Press Release

Richey LN, et al. M240. Associations of prior head injury with mild behavioral impairment domains. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.

Tandra G, et al. M189. Literature-based discovery to assess Parkinson’s disease adjuvants to levodopa. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.